Skip to main content
SpringerLink
Log in

Application of Pharmacologic Principles in the Evaluation of New Antiarrhythmic Agents

  • Chapter
Sudden Cardiac Death and Congestive Heart Failure: Diagnosis and Treatment

Part of the book series: Developments in Cardiovascular Medicine ((DICM,volume 25))

  • 46 Accesses

Abstract

One of the major goals of investigations of new drug therapy is the establishment of practical guidelines for patient management. Some drugs are found to have very wide margins between the dosages that produce desired effects and those causing adverse reactions. Developing guidelines for the use of such drugs is not likely to be a problem because interpatient pharmacologic variability is insignificant compared to the width of this therapeutic window. However, the therapeutic window is often very small for cardioactive drugs. Therefore, information on any factor which contributes to interindividual variability in response may be helpful in maximizing therapeutic effects while minimizing the risk of adverse reactions.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 129.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 169.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. McDevitt, D.G., Nies, A.S., Wilkinson, G.R., Smith, R.F., Woosley, R.L., and Oates, J.A. Antiarrhythmic effects of a lidocaine congener, tocainide, 2– amino–2’,6’–propionoxylidide, in man. Clin. Pharmacol. Ther. 19: 396–402, 1976.

    CAS  Google Scholar 

  2. Roden, D.M., Reele, S.B., Higgins, S.B., Mayol, R.F., Gammans, R.E., Oates, J.A., and Woosley, R.L. Total suppression of ventricular arrhythmias by encainide. New Engl. 3. Med. 302: 877–882, 1980.

    Article  PubMed  CAS  Google Scholar 

  3. Roden, D.M., Reele, S.B., Higgins, S.B., Wilkinson, G.R., Smith, R.F., Oates, J.A., and Woosley, R.L. Antiarrhythmic efficacy, pharmacokinetics and safety of N–acetylprocainamide in human subjects: comparison with procainamide. Amer. 3. Cardiol. 46: 463–468, 1980.

    Article  PubMed  CAS  Google Scholar 

  4. Winkle, R.A., Mason, J.W., Griffin, 3.C., and Ross, D. Malignant ventricular tachyarrhythmias associated with the use of encainide. Amer. Heart 3. 102: 857–864, 1981.

    Article  Google Scholar 

  5. Sheiner, L.B., Rosenberg, B., and Marathe, V.V. Estimation of population characteristics of pharmacokinetic parameters from routine clinical data. J. Pharmacokin. Biopharmac. 5: 445–479, 1977.

    Article  CAS  Google Scholar 

  6. Drayer, D.E., Lowenthal, D.T., Woosley, R.L., Nies, A.S., Schwartz, A., and Reidenberg, M.M. Cumulation of N–acetylprocainamide, an active metabolite of procainamide, in patients with impaired renal function. Clin. Pharmacol. Ther. 22: 63–69, 1977.

    PubMed  CAS  Google Scholar 

  7. Guentert, T.W., Upton, R.A., Holford, N.H.G., and Riegelman, S. Divergency in pharmacokinetic parameters of quinidine obtained by specific and nonspecific assay methods. J. Pharmacokin. Biopharmac. 7: 303–311, 1979.

    Article  CAS  Google Scholar 

  8. Lindenbaum, J., Mellow, M.H., Blackstone, M.O., and Butler, Jr., V.P. Variation in biologic availability of digoxin from four preparations. New Engl. J. Med. 285: 1344–1347, 1971.

    Article  PubMed  CAS  Google Scholar 

  9. Anderson, J.L., Patterson, E., Wagner, J.G., Stewart, J.R., Behm, H.L., Lucchesi, B.R. Oral and intravenous bretylium disposition. Clin. Pharmacol. Ther. 28: 468–478, 1980.

    Article  PubMed  CAS  Google Scholar 

  10. Boyes, R.N, Scott, D.B., Jebson, P.J., Godman, M.J., and Julian, D.G. Pharmacokinetics of lidocaine in man. Clin. Pharmacol. Ther. 12: 105–116, 1971.

    PubMed  CAS  Google Scholar 

  11. Wood, A.J.J., Carr, K., Vestal, R.E., Belcher, S., Wilkinson, G.R., and Shand, D.G. Direct measurement of propranolol bioavailability during accumulation to steady–state. Br. J. Clin. Pharmac. 6: 345–350, 1978.

    CAS  Google Scholar 

  12. Wang, T., Roden, D.M., Wolfenden, H.T., Woosley, R.L., Wilkinson, G.R., and Wood, A.J.J. Pharmacokinetics of encainide and its metabolites in man. Clin. Pharmacol. Ther. 31: 278, 1982 (abstract).

    Google Scholar 

  13. Narang, P.K., Crouthamel, W.G., Carliner, N.H., and Fisher, M.L. Lidocaine and its active metabolites. Clin. Pharmacol. Ther. 654–662, 1978.

    Google Scholar 

  14. Elharrar, V. and Zipes, D.P. Effects of encainide and metabolites (M314030 and M39444) on canine purkinje and ventricular fibers. J. Pharm. Exp. Ther. 220: 440–447, 1981.

    Google Scholar 

  15. Roden, D.M., Duff, H.J., Altenbern, D. and Woosley, R.L. Antiarrhythmic activity of the O–demethyl metabolite of encainide. J. Pharmacol. Exp. Ther. 221: 552–557, 1981.

    Google Scholar 

  16. De Boer, A.G., Breimer, D.D., Mattie, H., Pronk, J., and Gubbens–Stibbe, J.M. Rectal bioavailability of lidocaine in man: Partial avoidance of “first–pass”metabolism. Clin. Pharmacol. Ther. 26: 701–709, 1979.

    PubMed  Google Scholar 

  17. Wood, A.J.J., Kornhauser, D.M., Wilkinson, G.R., Shand, D.G., and Branch, R.A. The influence of cirrhosis on steady–state blood concentrations of unbound propranolol after oral administration. Clin. Pharmacokin. 3:478–487, 1978.

    Article  CAS  Google Scholar 

  18. Benowitz, N.L. and Meister, W. Clinical pharmacokinetics of lidocaine. Clin. Pharmacokin. 3:177–204, 1978.

    Article  CAS  Google Scholar 

  19. Greenblatt, D.J., Bolognini, V., Koch–Weser, J., and Harmatz, J.S. Pharmacokinetic approach to the clinical use of lidocaine intravenously. 3AMA 236: 273–277, 1976.

    Article  PubMed  CAS  Google Scholar 

  20. Anderson, J.L., Patterson, E., Conlon, M., Pasyk, S., Pitt, B., and Lucchesi, B.R. Kinetics of antifibrillatory effects of bretylium: Correlation with myocardial drug concentrations. Amer. J. Cardiol. 46: 583–589, 1980.

    Article  PubMed  CAS  Google Scholar 

  21. Lima, J.J., Boudoulas, H., and Blanford, M. Concentration–dependence of disopyramide binding to plasma protein and its influence on kinetics and dynamics. J. Pharmacol. Exp. Ther. 219: 741–747, 1981.

    PubMed  CAS  Google Scholar 

  22. Gugler, R., Shoeman, D.W., Huffman, D.H., Cohlmia, 3.B., and Azarnoff, D.L. Pharmacokinetics of drugs in patients with the nephrotic syndrome. J. Clin. Invest. 55: 1182–89, 1975.

    Article  PubMed  CAS  Google Scholar 

  23. Schenck–Gustafsson, K., Jogestrand, T., Nordlander, R., and Dahlqvist, R. Effect of quinidine on digoxin concentration in skeletal muscle and serum in patients with atrial fibrillation. New Engl. J. Med. 305: 209–212, 1981.

    Article  PubMed  CAS  Google Scholar 

  24. Woosley, R.L., and Shand, D.G. Pharmacokinetics of antiarrhythmic drugs. Amer. J. Cardiol. 41: 986–995, 1978.

    Article  CAS  Google Scholar 

  25. Thomson, P.D., Melmon, K.L., Richardson, J.A., Cohn, K., Steinbrunn, W., Cudihee, R., Rowland, M. Lidocaine pharmacokinetics in advanced heart failure, liver disease, and renal failure in humans. Ann. Int. Med. 78:499–508, 1973

    PubMed  CAS  Google Scholar 

  26. Richens, A. Clinical pharmacokinetics of phenytoin. Clin. Pharmacokin. 4: 153–169, 1979.

    Article  CAS  Google Scholar 

  27. Hager, W.D., Fenster, P., Mayersohn, M., Perrier, D., Graves, P., Marcus, F.I., and Goldman, S. Digoxin–quinidine interaction. New Engl. J. Med. 300: 1238–1241, 1979.

    Article  PubMed  CAS  Google Scholar 

  28. Kluger, J., Leech, S., Reidenberg, M.M., Lloyd, V., and Drayer, D.E. Long– term antiarrhythmic therapy with acetylprocainamide. Amer. J. Cardiol. 48: 1124–1130, 1981.

    Article  PubMed  CAS  Google Scholar 

  29. Jaillon, P., Rubenson, D., Peters, F., Mason, J.W., and Winkle, R.A. Electrophysiologic effects of N–acetylprocainamide in human beings. Amer. J. Cardiol. 47: 1134–1140, 1981.

    Article  PubMed  CAS  Google Scholar 

  30. Meinertz, T., Kasper, W., Kersting, F., Just, H., Bechtold, H., Jahnchen, E. Locainide II. Plasma concentration–effect relationship. Clin. Pharmacol. Ther. 26: 187–195, 1979.

    PubMed  Google Scholar 

  31. Jackman, W.M., Zipes, D.P., Naccarelli, G.V., Rinkenberger, R.L., Heger, J.J., and Prystowsky, E.N. Electrophysiology of oral encainide. Amer. J. Cardiol. 49: 1270–1278, 1982.

    Article  CAS  Google Scholar 

  32. Drayer, D.E., Lowenthal, D.T., Restivo, K.M., Schwartz, A., Cook, C.E., and Reidenberg, M.M. Steady–state serum levels of quinidine and active metabolites in cardiac patients with varying degrees of renal function. Clin. Pharm. Ther. 24: 31–39, 1978.

    CAS  Google Scholar 

  33. Grant, A.M., Marshall, R.J., Ankier, S.I. Some effects of disopyramide and its N–dealkylated metabolite on isolated nerve and cardiac muscle. Eur. J. Pharmacol. 49: 389–394, 1978.

    Article  PubMed  CAS  Google Scholar 

  34. Murphy, P.J. Metabolic pathways of aprindine. Acta Cardiol. (Brux) S18:1176

    Google Scholar 

  35. Meffin, P.J., Winkle, R.A., Blaschke, T.F., Fitzgerald, J., Harrison, D.C. Response optimization of drug dosage: antiarrhythmic studies with tocainide. Clin. Pharmacol. Ther. 22: 42–56, 1977.

    PubMed  CAS  Google Scholar 

  36. Roden, D.M., Reele, S.B., Higgins, S.B., Carr, R.K., Smith, R.F., Oates, J.A., and Woosley, R.L. Tocainide therapy for refractory ventricular arrhythmias. Amer. Heart J. 100: 15–22, 1980.

    Article  PubMed  CAS  Google Scholar 

  37. Alderman, E.L., Kerber, R.E., and Harrison, D.C. Evaluation of lidocaine resistance in man using intermittent large–dose infusion techniques. Amer. J. Cardiol. 34: 342–347, 1974.

    Article  PubMed  CAS  Google Scholar 

  38. Feely, J., Wilkinson, G.R., and Wood, AJJ. Reduction of liver blood flow and propranolol metabolism by cimetidine. New Engl. J. Med. 304: 692–695, 1981.

    Article  PubMed  CAS  Google Scholar 

  39. Shand, D.G., Desjardins, R.E., and Bjornsson, T.D. The method of separate exponentials: a simple aid to devising drug loading regimens. Clin. Pharm. Ther. 29: 542–549, 1981.

    Article  CAS  Google Scholar 

Download references

Authors
  1. Dan M. Roden M.D
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Raymond L. Woosley M.D., Ph. D.
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Likoff Cardiovascular Institute of Hahnemann Medical College and Hospital, Philadelphia, PA, USA

    J. Morganroth M.D.

  2. School of Veterinary Medicine, University of Pennsylvania, Philadelphia, PA, USA

    E. Neil Moore D.V.M., Ph.D.

Rights and permissions

Reprints and permissions

Copyright information

© 1983 Martinus Nijhoff Publishers, Boston

About this chapter

Cite this chapter

Roden, D.M., Woosley, R.L. (1983). Application of Pharmacologic Principles in the Evaluation of New Antiarrhythmic Agents. In: Morganroth, J., Moore, E.N. (eds) Sudden Cardiac Death and Congestive Heart Failure: Diagnosis and Treatment. Developments in Cardiovascular Medicine, vol 25. Springer, Boston, MA. https://doi.org/10.1007/978-1-4613-3876-5_2

Download citation

  • DOI: https://doi.org/10.1007/978-1-4613-3876-5_2

  • Publisher Name: Springer, Boston, MA

  • Print ISBN: 978-1-4613-3878-9

  • Online ISBN: 978-1-4613-3876-5

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation